Braj News Magazine

Metastatic Castration-Resistant Prostate Cancer Pipeline Insight Report | 75+ Companies and 75+ Drugs

 Breaking News
  • No posts were found

Metastatic Castration-Resistant Prostate Cancer Pipeline Insight Report | 75+ Companies and 75+ Drugs

January 16
18:40 2023
Metastatic Castration-Resistant Prostate Cancer Pipeline Insight Report | 75+ Companies and 75+ Drugs

DelveInsight’s, “Metastatic Castration-Resistant Prostate Cancer Pipeline Insight 2023” report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in the Metastatic Castration-Resistant Prostate Cancer pipeline landscape. It covers the Metastatic Castration-Resistant Prostate Cancer pipeline drug profiles, including Metastatic Castration-Resistant Prostate Cancer clinical trials and nonclinical stage products. It also covers the Metastatic Castration-Resistant Prostate Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key takeaways from the Metastatic Castration-Resistant Prostate Cancer Pipeline

  • DelveInsight’s Metastatic Castration-Resistant Prostate Pipeline Report depicts a robust space with 75+ active players working to develop 75+ pipeline therapies for metastatic castration-resistant prostate cancer treatment.
  • The leading Metastatic Castration-Resistant Prostate Companies are working in the market include AstraZeneca, Hinova pharmaceuticals, POINT Biopharma, Exelixis, Tavanta Therapeutics, Pfizer, Zenith Epigenetics, Surface Oncology, Opna-IO LLC, Taiho oncology, Arvinas, Forma therapeutics, ESSA Pharma, Oncternal, Janux Therapeutics, Blue Earth Therapeutics, Arcus Biosciences, Fortis therapeutics, Amgen,  Regeneron Pharmaceuticals, Veru Inc, Constellation Pharmaceuticals, Noxopharm Limited, Immunic AG, Accutar Biotechnology Inc, Hinova pharmaceuticals, Novartis, Nuvation Bio, Bayer, Cardiff Oncology, Astellas Pharma, Hoffman-La-Roche, Modra Pharmaceuticals, Bristol Myers Squibb, Bellicum Pharmaceuticals and others are developing novel drug candidates to improve the metastatic castration-resistant prostate cancer treatment landscape.
  • Promising Metastatic Castration-Resistant Prostate Pipeline Therapies includes Capivasertib, TAVT-45, HC-1119, PNT2002, Cabozantinib, TAVT-45, ZEN-3694, SRF 617, PLX2853, REGN5678, VERU-100, CPI-1205, NOX66, IMU-935, AC176, HP518, NZV930, NIR178, NUV 422, XL092, VERU-111, BAY2315497, Onvansertib, Enfortumab vedotin, Talazoparib, and others.
  • The Metastatic Castration-Resistant Prostate Companies and academics are working to assess challenges and seek opportunities that could influence R&D Metastatic Castration Resistant Prostate cancer. The Metastatic Castration-Resistant Prostate pipeline therapies under development are focused on novel approaches to treat/improve Metastatic Castration Resistant Prostate cancer.

 

Discover the recent breakthroughs and advances in metastatic castration-resistant prostate cancer drug treatment @ Metastatic Castration-Resistant Prostate Cancer Pipeline Outlook

 

Recent Developmental Activities in the Metastatic Castration-Resistant Prostate Cancer Treatment Landscape

  • In January 2022, Hinova Pharmaceuticals announced that the first patient with metastatic castration-resistant prostate cancer (mCRPC) had been successfully dosed in Phase I clinical trial of HP518, a highly selective and orally bioavailable chimeric degrader targeting androgen receptor (AR). The ongoing open-label Phase I study in Australia will evaluate the safety, pharmacokinetics, and anti-tumor activity of HP518 in patients with mCRPC.
  • In December 2021, Accutar Biotechnology announced the FDA clearance of the IND application for Phase I Trial of AC0176 in prostate cancer. Accutar expects to begin enrollment in Phase 1 clinical trial for AC0176 in the first quarter of 2022.
  • In April 2022Janssen announced the submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) seeking approval of niraparib in combination with abiraterone acetate, in the form of a dual-action tablet plus prednisone, based on the results of the Phase III MAGNITUDE study for the treatment of patients with prostate cancer who have progressed to metastatic castration-resistant prostate cancer (mCRPC) and are positive for homologous recombination repair (HRR) gene alterations. In April 2016, Janssen Biotech, Inc. entered a worldwide (except Japan) collaboration and license agreement with TESARO, Inc. (acquired by GSK in 2018), for exclusive rights to niraparib in prostate cancer.
  • In May 2022, Janux Therapeutics announced that the US Food and Drug Administration (FDA) cleared the Company’s investigational new drug (IND) application for its lead product candidate, JANX007, a PSMA-TRACTr in development for the treatment of metastatic castration-resistant prostate cancer (mCRPC). JANX007 is the Company’s lead novel T cell engager (TCE) therapeutic from its TRACTr platform. Janux plans to initiate a Phase I clinical trial for JANX007 in the second half of 2022.
  • In June 2022, Blue Earth Therapeutics announced results from a series of preclinical analyses designed to evaluate the biodistribution and potential therapeutic efficacy of 177Lu-rhPSMA-10.1 and 177Lu-PSMA-I&T in the treatment of prostate cancer preclinical models. In April 2022, the FDA cleared an investigational new drug application for 177Lu-rhPSMA-10.1 as a potential therapeutic option for patients with metastatic castration-resistant prostate cancer (mCRPC). 
  • Oncternal is supporting an investigator-sponsored study being conducted at the UC San Diego School of Medicine, a Phase Ib clinical trial of  zilovertamab in combination with docetaxel for patients with metastatic castration-resistant prostate cancer (mCRPC). In addition, it is also developing ONCT-534, a dual-action androgen receptor inhibitor (DAARI), that is in preclinical development as a potential treatment for castration-resistant prostate cancers, including those with clinically important resistance to approved androgen receptor inhibitors.
  • In June 2022ESSA Pharma Inc. presented clinical results from the Phase Ia dose-escalation study of EPI-7386, ESSA’s first-in-class N-terminal domain androgen receptor inhibitor, as a monotherapy for the treatment of patients with metastatic castration-resistant prostate cancer resistant to current standard-of-care therapies. The initial data from 36 patients demonstrated that EPI-7386 was well-tolerated, exhibited a favorable pharmacokinetic profile, and demonstrated initial anti-tumor activity in a heavily pretreated group of patients. ESSA expects to initiate the Phase Ib expansion study in Q3 2022.
  • In May 2022Arcus Biosciences reported that data analysis from the randomized cohort of ARC-6 evaluating etrumadenant plus zimberelimab and docetaxel versus docetaxel in second-line metastatic castrate-resistant prostate cancer (CRPC) is anticipated in the second half of 2022 with a presentation of results expected in 2023.
  • In February 2022Arvinas reported that the novel androgen receptor (AR) PROTAC degrader, bavdegalutamide (ARV-110), was found to be clinically active and tolerable with manageable adverse effects (AEs) in Phase I/II clinical trial in patients with metastatic castration-resistant prostate cancer (mCRPC) following 1 to 2 prior novel hormonal drugs.
  • In March 2022Forma therapeutics reported positive results from Phase I clinical trial evaluating FT-7051. It was well tolerated with signs of clinical activity and continues to enroll men with metastatic castration-resistant prostate cancer (mCRPC). The first evaluable patient completing 12 weeks of treatment demonstrated a >80% decline in prostate-specific antigen (PSA80) from baseline at 16 weeks with stable disease. As of May 2022, 25 patients were enrolled in the Phase I dose-escalation trial, assessing the predicted efficacious exposure range supported by target engagement.  Future trial enrollment to include less heavily pre-treated patients and alternative dosing schedules to address adverse events, with updated results expected in the first half of 2023.

 

Metastatic Castration Resistant Prostate Cancer Overview

Prostate cancer (PCa) is one of the most prevalent malignancies in the world and the third most common cause of male cancer-related death in the United States of America (USA). The majority of men with newly diagnosed PCa present with localized disease and undergo radical prostatectomy and/or radiological therapy, followed by androgen deprivation therapy (ADT). Depending on the grade of the cancer, a variable percentage of these patients experience progression to castration-resistant prostate cancer (CRPC) within 10 years. CRPC was previously named “hormone-refractory prostate cancer” and “androgen-independent prostate cancer”. However, because castration treatments including ADT were ineffective, these cancers still showed reliance upon hormones for androgen receptor (AR) activation.

 

Find out more about metastatic castration-resistant prostate cancer treatment and Medication @ Metastatic Castration-Resistant Prostate Cancer Treatment Landscape

 

Metastatic Castration Resistant Prostate cancer Emerging Drugs

 

SRF617: Surface Oncology

SRF617 is a fully human antibody designed to inhibit the enzymatic activity of CD39 in the tumor microenvironment, allowing for a dual mechanism of action to promote anti-tumor immunity via reduction of immunosuppressive adenosine in addition to increasing levels of immunostimulatory ATP. SRF617 has been granted Orphan Drug designation for the treatment of advanced pancreatic cancer by the FDA.

 

Rucaparib: Clovis Oncology

Rucaparib is an oral, small molecule inhibitor of PARP1, PARP2 and PARP3 being developed in multiple tumor types, including ovarian and metastatic castration-resistant prostate cancers, as monotherapy, and in combination with other anti-cancer agents. Exploratory studies in other tumor types are also underway.

 

HP518: Hinova Pharmaceuticals

HP518, a highly selective and orally bioavailable chimeric degrader targeting androgen receptor (AR) with the potential to overcome the drug resistance of prostate cancer due to some specific AR mutations. In discovery and preclinical studies, HP518 showed high degradation activity against wild type AR and some specific AR mutants that are resistant to enzalutamide, and excellent antitumor activity in xenograft mouse models. HP518 is highly selective for AR.

 

Metastatic Castration Resistant Prostate Cancer Therapeutic Assessment

There are approx. 75+ key companies which are developing the therapies Metastatic Castration Resistant Prostate cancer. The companies which have their Metastatic Castration Resistant Prostate cancer drug candidates in the most advanced stage, i.e phase III include Clovis Oncology.

 

Learn more about the novel and emerging metastatic castration-resistant prostate cancer therapies @ Metastatic Castration-Resistant Prostate Cancer Ongoing Clinical Trials Analysis

 

Scope of the Metastatic Castration-Resistant Prostate Cancer Pipeline Report

  • Coverage- Global
  • Metastatic Castration-Resistant Prostate Cancer Companies- AstraZeneca, Hinova pharmaceuticals, POINT Biopharma, Exelixis, Tavanta Therapeutics, Pfizer, Zenith Epigenetics, Surface Oncology, Opna-IO LLC, Taiho oncology, Arvinas, Forma therapeutics, ESSA Pharma, Oncternal, Janux Therapeutics, Blue Earth Therapeutics, Arcus Biosciences, Fortis therapeutics, Amgen,  Regeneron Pharmaceuticals, Veru Inc, Constellation Pharmaceuticals, Noxopharm Limited, Immunic AG, Accutar Biotechnology Inc, Hinova pharmaceuticals, Novartis, Nuvation Bio, Bayer, Cardiff Oncology, Astellas Pharma, Hoffman-La-Roche, Modra Pharmaceuticals, Bristol Myers Squibb, Bellicum Pharmaceuticalsand others.
  • Metastatic Castration-Resistant Prostate Cancer Pipeline Therapies- Disitamab Vedotin, EndoTAG®-1 (SB05), Stenoparib (2X-121), U3-1402, KN026, trastuzumab duocarmazine, HS-10342, MRG002, ARX788, DHP107, PMD-026, PVX-410, HX008, Tenalisib, MEN1611, SM-88, HMPL-013, ODM-209, HC-5404-FU, RP12146, PU-H71, NOV120101, SC10914, Eftilagimod Alpha, ARV-471, E7090, DZD1516, G1T38, Sitravatinib, TQ-B211, B003, PF-06873600, OTS167PO, AND019, DAN-222, Enobosarm, Futibatinib, LY3484356, Lasofoxifene, MCLA-128, huMNC2-CAR44 CAR T cells, REM-001, GNC-035, RGT-419B, Hemay022, SCR-6852, and others.
  • Metastatic Castration-Resistant Prostate Cancer Segmentation- Phases, Molecule Type, Mechanism of Action, Route of Administration

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Metastatic Castration Resistant Prostate cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Metastatic Castration Resistant Prostate cancer– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Rucaparib: Clovis Oncology
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Surface Oncology: SRF 617
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. REGN 4336: Regeneron Pharamceuticals
  15. Drug profiles in the detailed report…..
  16. Early Stage Products (Phase I)
  17. HP 518: Hinova Pharmaceuticals
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Metastatic Castration Resistant Prostate cancer Key Companies
  21. Metastatic Castration Resistant Prostate cancer Key Products
  22. Metastatic Castration Resistant Prostate cancer- Unmet Needs
  23. Metastatic Castration Resistant Prostate cancer- Market Drivers and Barriers
  24. Metastatic Castration Resistant Prostate cancer- Future Perspectives and Conclusion
  25. Metastatic Castration Resistant Prostate cancer Analyst Views
  26. Metastatic Castration Resistant Prostate cancer Key Companies
  27. Appendix

 

For further information on the metastatic castration-resistant prostate cancer pipeline drugs therapeutics, reach out to Metastatic Castration-Resistant Prostate Cancer Key Companies and Therapies

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/